Augmentation therapy with alpha1-antitrypsin: novel perspectives

Area of Science:

• Biochemistry
• Immunology
• Genetics

Background:

• Alpha-1 antitrypsin (AAT) is a key circulating protease inhibitor.
• Inherited AAT deficiency, particularly the Z mutation, leads to misfolded protein polymerization, causing emphysema and liver disease.
• Reduced AAT levels are linked to various other conditions, including infections and inflammatory diseases.

Purpose of the Study:

• To review the established role of AAT in emphysema and liver disease.
• To explore novel associations between AAT levels and other human diseases.
• To discuss the potential of AAT therapy for broader clinical applications based on its anti-inflammatory and immunomodulatory effects.

Main Methods:

• Literature review of AAT deficiency and its clinical manifestations.
• Analysis of recent studies linking AAT levels to various diseases.
• Examination of experimental data on AAT's anti-inflammatory and immunomodulatory properties.

Main Results:

• AAT deficiency is strongly associated with early-onset pulmonary emphysema and liver disease due to protein misfolding and reduced circulating levels.
• Emerging evidence connects lower AAT levels with HIV, hepatitis C, diabetes, vasculitis, and panniculitis.
• AAT therapy, currently used for emphysema, demonstrates significant anti-inflammatory and immunomodulatory effects in experimental models.

Conclusions:

• AAT deficiency has broader implications than previously understood, affecting multiple organ systems.
• AAT therapy's anti-inflammatory and immunomodulatory actions suggest potential for treating a wider range of inflammatory and immune-related conditions.
• Further clinical investigation into AAT therapy for non-emphysema related diseases is warranted.